Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in Obesity

Endevica Bio Unveils Differentiated Mechanism for Durable Weight Loss in Obesity

NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ -- Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape for general obesity treatment. The company's research demonstrates that co-agonism…

Endevica Bio reports co-agonism of the melanocortin-3 and -4 receptors drives robust weight loss

Endevica Bio has announced that the co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss, unlocking the melanocortin system as a differentiated mechanism of action to complement and rival current obesity treatments. The company stated that this finding could redefine the therapeutic landscape for general obesity treatment.For decades, MC4R has been recognised as a key target for obesity. Despite its pr…